Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Current antithrombotic therapies (anticoagulants, platelet antagonists) carry a significant bleeding risk.
• Developing safer antithrombotic strategies with reduced bleeding complications is a major clinical need.

Purpose of the Study:

• To develop novel antithrombotic agents that inhibit polyphosphate (polyP) with high specificity and minimal bleeding risk.
• To identify and characterize lead compounds from a library of macromolecular polyanion inhibitors (MPI).

Main Methods:

• Screening of a molecular library to identify MPI with high binding affinity and specificity for polyP.
• Evaluating lead MPI candidates for antithrombotic activity in mouse models of thrombosis.
• Assessing the bleeding risk and tolerability of lead MPI candidates in mice.

Main Results:

• Lead MPI candidates demonstrated potent antithrombotic activity in preclinical models.
• These MPI did not induce bleeding, even at high doses.
• The developed inhibitors showed excellent tolerability in mouse models.

Conclusions:

• Macromolecular polyanion inhibitors (MPI) represent a promising new class of antithrombotic agents.
• MPI offer a potential therapeutic strategy for thrombosis prevention without the associated bleeding risk, addressing a critical unmet need.